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Abstract 
Hepatitis C is disease that damages the liver and it is caused by the hepatitis C virus (HCV). The 
pathology became chronic in about 80% of the cases due to virus persistence in the host organism. 
The standard-of-care consists of peghylated-interferon plus ribavirin, however the treatment 
response is very variable and different host/viral factors may concur in the disease outcome. 
The mannose-binding protein C (MBL) is a component of the innate immune system, able to 
recognize HCV and consecutively activating the immune response. MBL is encoded by MBL2 gene 
and polymorphisms, two in the promoter region (H/L and X/Y) and three in exon 1 (at codon 52, 54 
and 57) have been described as functionally influencing protein expression. 
In this work 203 Italian HCV patients and 61 healthy controls were enrolled and genotyped for the 
five MBL2 polymorphisms mentioned above in order to investigate their role in HCV infection 
susceptibility, spontaneous viral clearance and treatment response. MBL2 polymorphisms were not 
associated with HCV infection susceptibility, and with spontaneous viral clearance, while MBL2 O 
allele, O/O genotype, HYO haplotype and DP combined genotype (all correlated with low or 
deficient MBL expression) were associated with sustained virological response. 
Moreover a meta-analysis to assess the role of MBL2 polymorphisms in HCV infection 
susceptibility was also performed: YA haplotype could be associated with protection towards HCV 
infection. 
 
Keywords: hepatitis C, innate immunity, MBL2 
 
Introduction 
Hepatitis C is a common hepatic disease caused by infection with the Hepatitis C Virus (HCV) 
affecting globally around 130-150 million persons [1]. 
Patients are frequently asymptomatic during the acute phase of infection and most of them (about 
80%) are not able to clear the virus: so the infection becomes chronic, possibly progressing to 
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chronic liver disease, cirrhosis and hepatocellular carcinoma [2]. The HCV infected patients have 
been usually treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) [3] but this 
treatment accomplishes a sustained virological response (SVR) only in about 50% of the subjects 
[4] and it is frequently correlated with toxicity and with the generation of adverse effects [5]. 
The etiopathogenetic mechanism at the basis of liver injury as well as treatment response are not yet 
clearly understood and several efforts have been made to highlight the potential factors involved in 
this multifactorial phenotype [6, 7]. Individuals infected with HCV genotypes 1 [8] and 4 [9] are 
less responsive to PEG-IFN/RBV treatment than those with genotypes 2 and 3 [10]. 
 
Likewise it is widely assessed that the host immune system and particularly the innate components, 
representing the first line of host defence, could play an important role in the response to viral 
infection as well as to the treatment. Specifically toll-like receptor and RNA helicases retinoic acid 
inducible gene-I and melanoma differentiation antigen 5 have been reported as able to recognize 
virus and to activate the antiviral immune response [11], instead interferons are the principal 
cytokines produced, in particular the better known molecule associated with treatment response is 
Int rferon-λ3, firstly identified by Ge et al. in 2009 [12]. Another important component of the 
innate immune system the mannose-binding protein C (MBL) potentially possesses a functional 
activity against HCV, since HCV E2 envelope glycoprotein has 11 N-linked glycosylation sites 
with mannose residues that could be recognized by this molecule [13]. The MBL binding leads to 
the activation of lectin pathway resulting in the complement cascade that finishes in the cleavage of 
C3 in C3a and C3b. C3b is deposited on virions or virus infected cells thus promoting virions 
aggregation, antigen presenting cells recruitment and other pro-inflammatory activities [14]. 
 
MBL serum level are known to be under genetic control: three point mutations in its encoding gene, 
MBL2 (10q11.1-q21) at codon 52 (C>T, rs5030737), 54 (G>A, rs1800450) and 57 (G>A, 
rs1800451) in exon 1, named as D, B and C alleles, respectively (collectively designated as allele O, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
while the normal allele is called A) have been associated with low MBL concentrations [15]. In 
addition, other polymorphisms have been also described in the promoter region of the gene: the H 
and L at position 550 (rs11003125), are in linkage disequilibrium with the X and the Y variant at 
position 221 (rs7096206) that, combined with the variant at exon 1, form the six main haplotypes 
HYA, LYA, LXA, HYD, LYB and LYC, correlated with different protein serum level [16].  
 
MBL2 genetic variants, responsible for low MBL expression, have been previously associated with 
HCV infection susceptibility among Brazilians [17-19] and with less efficient HCV clearance 
during interferon therapy among Japaneses [20].  
So, with the aim of better disclose the possible role of MBL2 genetic variants in the context of HCV 
infection susceptibility, spontaneous viral clearance and response to PEG-INF/RBV therapy, as well 
as replicating previous findings in a novel population of different ethnic background, an association 
study was performed analysing MBL2 polymorphisms in a group of HCV infected patients and 
healthy controls from North-East of Italy. 
Additionally a meta-analysis was performed to unravel the possible role of MBL2 genetic variants 
in HCV infection 
 
Materials and methods  
Study population 
Two hundred and three patients were enrolled at the unit “Clinica Medica”, Cattinara Hospital and 
“Italian Liver Foundation” Trieste (Italy): 117 presented with HCV positive chronic hepatitis, 7 
with spontaneous HCV clearance (SVC) and 79 patients that cleared the infection after therapy 
(European-Caucasian, 87 woman and 116 man, mean age=62, standard deviation=14.23, range=26-
90).  
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Among the HCV chronic patients, the inclusion criteria were: chronic hepatitis with histological 
diagnosis, HCV-RNA positive with a PCR test, alanine transaminase higher than 1.5 times in the 
last 6 months, age greater of 18 years; criteria of exclusion from the study were: no hepatic lesions, 
hepatocellular carcinoma, HIV co-infection, Hepatitis B surface antigen positivity, alcoholic or drug 
abusers, autoimmunity disorder (serum autoantibody), psychiatric disease with pharmacological 
treatment, anaemia, alfa1antitrispina deficit, Wilson disease. 
 
All patients have been diagnosed hepatitis C infection through HCV RNA detection (COBAS 
Ampliprep / COBAS Taqman HCV Test, Roche, Basel, Switzerland) and serological analysis of 
anti-HCV antibody using enzyme immunoassay and confirmed with recombinant immunoblot assay 
(Ortho Diagnostic Systems, Raritan, NJ, USA). All patients were seronegative for hepatitis B and 
HIV serological markers.  
 
HCV RNA genotyping was conducted with the INNO-LiPA HCV Genotyping kit, (Innogenetics)  
One-hundred and sixty-tree patients followed the standard therapy that consisted of peghylated 
Int rferon plus ribavirin: patients with HCV genotype type 2 and 3: peghylated interferon 180 μg/kg 
weekly, ribavirin 800-1200 mg daily, weight dependent, for 24 weeks, patients with genotypes 1 
and 4, peghylated interferon 180 μg/kg weekly, ribavirin 800-1200 mg daily, weight dependent for 
48 weeks. The patients underwent periodical examinations after 1, 7, 14, 28 day and then every 4 
weeks. Treatment response was defined as sustained virological responder (SVR) if patients 
presented HCV RNA negativity during therapy and maintained this conditions in the follow-up 6 
months after the end of treatment; no responder (NR) when the therapy was not effective to 
eliminate the virus. 
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As healthy controls 61 healthy blood donor subjects (European-Caucasian, 32 woman and 29 man, 
mean age=45, standard deviation=9.88, range=22-67), known to be negative for HCV infection 
were enrolled at the “Centro Trasfusionale” of “Maggiore Hospital”, Trieste (Italy). 
A written free and informed consent was obtained from all subjects. All study experiments and 
procedures have been performed in accordance with the ethical standards of the 1975 Declaration of 
Helsinki (6
th
 revision, 2008). IRCCS Burlo Garofolo Ethical Committee approved the research 
project (CIB protocol L.-1055 N. 118/10). 
 
DNA Extraction 
Patients’ genomic DNA was extracted from whole blood using the DNA extractor NucliSENS® 
easyMAG® 2.0 (bioMérieux, Marcy l'Etoile, France) instrument according to the manufacturer’s 
protocol. 
 
MBL2 genotyping 
MBL2 polymorphisms have been genotyped using TaqMan SNPs genotyping assay and TaqMan 
GTXpress™ Master Mix on ABI7900HT Real Time PCR platform (Applied Biosystems - Life 
Technologies, Carlsbad, California, U.S.A.) following manufacturer’s instructions. 
 
Four MBL2 SNPs were genotyped using TaqMan pre developed SNPs genotyping assays: 
C__27858274_10 for promoter XY polymorphism (rs7096206); C___2336610_10 for exon 1 
52C>T polymorphism (rs5030737); C___2336609_20 for exon 1 54G>A polymorphism 
(rs1800450) and C___2336608_20 for exon 1 57G>A polymorphism (rs1800451). For the promoter 
HL polymorphism (rs11003125), a custom TaqMan SNP genotyping assay was developed. Allelic 
discrimination was done both manually and automatically with the SDS detection software version 
2.1 (Applied Biosystems). The specificity and sensitivity of the Taqman assays were double-
checked in blind on 50 DNAs with known MBL2 genotype: Taqman genotyping results were 100% 
concordant with the sequenced samples. 
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For the analysis, MBL2 polymorphisms were considered singularly, but also grouping together the 
three variants on MBL2 exon 1 as O allele, whereas the wild allele was termed A. The promoter-
exon 1 combined genotypes were associated with the protein level and were divided into high 
producer (HYA/HYA, HYA/LYA, LYA/LYA, HYA/LXA, LYA/LXA, referred as HP), low 
producer (LXA/LXA, HYA/O, LYA/ O, referred as LP) and deficient producer (LXA/O, O/O, 
referred as DP) as suggested by Garred et al. [21]. 
 
Statistical analysis 
Allele, genotype and haplotype frequencies of MBL2 polymorphisms were calculated by direct 
counting. The Fisher’s exact test for pairwise comparison of allele, genotype and haplotype 
frequencies (using contingency tables as appropriate) was performed with open-source R version 
3.1.3 [22], the adjustment for age and sex was performed with SNPassoc package for R [23], only 
p-values <0.05 were considered to be significant. Post-hoc power calculations were performed with 
G*Power software version 3.1.9.2 [24]. 
 
Meta-analysis 
The research of previous published articles was performed within PubMed database and the 
following key words were used: hepatitis C and mannose binding lectin. Analysis of MBL2 
haplotypes (YA, XA and YO) in HCV infection susceptibility was the inclusion criteria. The 
analysis was performed with Metafor package [25] for R: strength of association was assessed by 
the odds ratio (OR) and 95% confidence intervals (CI), the OR was calculated using YA haplotype 
as references (YA vs. XA and YA vs. YO). 
The ORs were analyzed using the random-effects model [26], if the heterogeneity test result was p-
value<0.1 or, if the heterogeneity test result was p-value>0.1, the fixed effects model was used [27]. 
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Results 
Study population 
Among the 203 HCV infected individuals enrolled for the study, 141 underwent the PEG-IFN/RBV 
therapy and 62 did not. Among the treated patients, 79 were SVR and 62 were NR, among the 
untreated patients 7 spontaneously cleared the virus (SVC), while 55 did not (NSVC). 
Patients were then stratified according to their HCV genotype, as infected by genotype 1 (79 among 
treated individuals; 47 among untreated patients) or infected by genotypes other than 1 (genotypes 
2, 3 or 4) (62 among treated subjects; 15 among untreated patients). 
All the groups and subgroups were in Hardy-Weinberg equilibrium for MBL2 polymorphisms 
analysed. 
 
MBL2 polymorphisms 
The comparison of MBL2 allelic and genotypic frequencies between the totalities of HCV infected 
individuals and healthy controls, are reported in table 1: no statistically significant results have been 
found, even when patients were divided in subjects infected with HCV genotype 1 or not 1 (data not 
shown). 
 
MBL2 allelic and genotypic frequencies were then confronted between sustained virus responder 
(SVR) and non responder (NR) individuals, without finding any statistically significant difference 
(table 2), also when stratifying for HCV genotype (table 3 and 4) with the exception of O allele and 
O/O genotype, significantly more frequent in SVR than NR in HCV genotype 1 infected individuals 
(p=0.01; CI=0.15-0.82; OR=0.35; p=0.03; CI=0.002-1.03; OR=0.10) (table 4) (power 
analysis=1.00) and after adjustment for age and sex the statistical significance remained (p=0.04, 
CI=0.01-0.95, OR=0.10) (data not shown).  
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No statistically significant associations were observed by comparing SVC and patients with no 
SVC, even when considering the HCV genotype (data not shown).  
Finally, five common MBL2 haplotypes were found, (HYA, LYA, LXA, HYO, LYO), further 
arranged in combined genotypes and grouped according to the corresponding MBL production [28]. 
The HYO haplotype was associated with SVR in treated patients (p=0.01; CI=001-0.65; OR=0.14) 
(table 2) (power analysis =1.00), also when considering only HCV genotype 1 infected individuals 
(p=0.02; CI=0.00-0.84; OR=0.10) (table 3) (power analysis >0.99). Similarly, also the deficient 
producer (DP) combined genotypes were associated with SVR in treated patients (p=0.04; CI=0.09-
0.94; OR=0.32)  (table 2) (power analysis >0.99) and after adjustment for age and sex the statistical 
significance became stronger (p=0.01, CI=0.06-0.60, OR=0.19) (data no shown).  
 
Meta-analysis 
Only three studies [17, 19, 29] agreed with the inclusion criteria and showed usable data: they 
inquired the association between HCV infection susceptibility and MBL2 functional haplotypes. 
The table 5 reports the basic characteristic of the studies. For the comparison between YA and XA 
haplotypes, the test for heterogeneity presented a p-value>0.05, therefore the Fixed Effects Model 
was chosen and it showed an association between the subjects carrying YA haplotype and 
protection against HCV infection (OR=0.75, CI=0.59-0.96) (figure 1), instead considering the YA 
and YO haplotype the test of heterogeneity had a p-value=0.03, so the Random Effect Model was 
used but no statistically significant results were observed (OR=0.84, CI=0.55-1.27) (figure 2). 
 
Although in the present study the haplotype power analysis was low (0.33) in the comparison 
between healthy controls and HCV patients, data from the current work were also included in the 
meta-analysis, but the statistical significance was lost (YA vs XA: test for heterogeneity p-
value>0.05, Fixed Effects Model, OR=0.83, CI=0.59-1.16; YA vs YO: test for heterogeneity p-
value=0.04, Random Effect Model, OR=0.88, CI=0.63-1.24). 
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Discussion 
Although MBL innate immunity molecule has been reported as possessing anti-viral activity against 
HCV in our study we did not find an association between functional MBL2 polymorphisms and 
susceptibility to be infected by HCV, in agreement with previous genetic studies [29-32], performed 
on ethnic groups different from the Italian one here analysed; moreover Killpatrick et al. described a 
lack of association between circulating serum levels of MBL and susceptibility towards hepatitis C 
infection [33]. On the other hand, three other studies have suggested an association of MBL2 
genetic variants with HCV infection susceptibility [17-19]. The differences encountered among the 
works mentioned above could be explained on the basis of different ethnic origin of the individuals 
analysed, being MBL2 polymorphisms frequencies different among populations [34], as well as 
considering the low number of patients and controls enrolled in all studies, this work included, 
finally taking into account the lack of an appropriate control group (with the same risk exposure of 
the infected patients). 
 
A meta-analysis was performed with data concerning three different populations (Euro-Brazilian, 
Brazilian and Japanese) from three studies [17-19, 29], the MBL2 YA haplotype was associated 
with HCV infection susceptibility compared to XA but not to YO haplotype; these results 
counteracted the negative findings of the current study (data not shown), however, when the results 
of the present study on Caucasian subjects were included in the meta-analysis the statistical 
significance was lost. 
Consequently it is possible to speculate that MBL2 polymorphisms might be not involved in HCV 
infection susceptibility, or if the association was present, was weak. 
In this study MBL2 polymorphisms were not associated with spontaneous viral clearance but 
besides no previous study investigated this issue, however only seven subjects eliminated naturally 
virus and this number is too low to provide enough statistical power supporting the role of MBL2 
genetic variants in the context of virus clearance. 
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Then considering the response to interferon treatment, an association was found between MBL2 
polymorphisms and SVR: the HYO haplotype and DP combined genotype were associated to SVR 
in treated individuals; in addition to HYO haplotypes, also MBL2 O/O genotype and O allele 
(correlated with low MBL serum levels [28]) were associated with SVR in individuals infected with 
genotype 1 HCV; the statistical power of these significant findings was high and corroborated the 
results.  
 
MBL has been previously reported as a double-edged sword in the context of HIV viral infection: 
high level of circulating proteins confer protection against virus infection, but once the virus infect 
the cell high MBL level are detrimental since enhancing the production of pro-inflammatory 
cytokines and consequently favouring viral replication [35]. So we can hypothesize a similar 
scenario for HCV where individuals with low MBL levels, should have a better control of HCV 
replication, consequently improving their response to the treatment.   Similarly to In contradiction 
with these findings, Matsushita et al.  [29] reported in a Japanese population that low producer 
alleles and haplotypes might be predictors for bad outcomes of interferon therapy, however the 
different ethnicity and the use of only IFN without RBV on Japanese HCV patients could explain 
the differences encountered. 
 
Conversely, Killpatrick et al. [33] and Dumestre-Perard et al. [36] didn’t show any influence of 
MBL serum expression on interferon therapy response. Furthermore no association was found 
between MBL2 polymorphisms and hepatitis outcome in treated Turkish [30] and Greek [37] HCV 
patient. 
MBL is an acute-phase reactant protein and its serum level would be increased after an acute 
infection [38], or regulated by interleukins, heat shock, and other biological triggers, some of which 
are interferon-inducible [39]. Additionally it has been speculated that complement mediated 
enhanced phagocytosis, as a result of opsonization, could facilitate intracellular infections [40] so in 
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some cases, high level of MBL protein could be disadvantageous for infected subjects and 
supported the pathogen spreading. Finally low level of protein production might moderate a strong 
complement-mediated activation that could result in tissue damage as observed in inflammatory 
situation [41]. However, as for susceptibility to HCV, MBL2 polymorphisms showed controversial 
results, possibly due to the limited number of samples analyzed and to ethnic differences; we have 
also to consider that susceptibility to HCV infection as well as the treatment response are 
multifactorial complex traits with many genes involved, so MBL2 being just a piece of the puzzle 
could have a limited influence on the phenotypes. 
 
The genetic factors that influence the natural course of HCV infection and the response to treatment 
are not yet fully understood [42, 43]. In this work MBL2 gene polymorphisms were analysed as 
potential factor involved in HCV infection susceptibility and therapy outcome. MBL2 
polymorphisms seemed to interfere marginally with interferon therapy response, and the literature 
showed concordant and discordant results with the present study. So, considering the main 
limitation of association analyses comparing the distribution of MBL2 polymorphisms in HCV 
inf cted individuals and healthy controls or between subjects with different response to interferon 
therapy, related to the low number of subjects enrolled and different ethnic background, only a 
collaborative study enrolling greater number of patients and control, such as those of GWAS, could 
disclose the true role of MBL2 in the modulation of these complex traits. If the association between 
MBL2 functional genetic variants and SVR will be confirmed, we can figure out the introduction of 
MBL2 genotyping, at present fully optimized and feasible by laboratory technicians in mass scale, 
in the clinical routine follow-up of HCV infected patients. 
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Table 1: MBL2 polymorphism allele, genotype and haplotype counts (and frequencies) in HCV 
infected patients (HCV) and healthy controls (HC) 
 
HCV infection HCV HC HCV vs. HC 
 n=203 n=61  
    
MBL2 H/L    
L 272 (0.67) 78 (0.64) ref 
H 134 (0.33) 44 (0.36) p=0.58; CI=0.56-1.37; OR=0.87 
L/L 87 (0.43) 23 (0.38) ref 
H/L 98 (0.48) 32 (0.52) p=0.54; CI=0.42-1.55; OR=0.81 
H/H 18 (0.09) 6 (0.10) P=0.78; CI=0.26-2.74; OR=0.79 
HWE χ2=1.70; p=0.19 χ2=1.15; p=0.28  
    
MBL2 X/Y    
Y 302 (0.74) 92 (0.75) ref 
X 104 (0.26) 30 (0.25) p=0.91; CI=0.65-1.75; OR=1.06 
Y/Y 110 (0.54) 34 (0.56) ref 
X/Y 82 (0.40) 24 (0.39) p=0.88; CI=0.56-2.01; OR=1.06 
X/X 11 (0.05) 3 (0.05) p=1.00; CI=0.28-6.68; OR=1.13 
HWE χ2=0.73; p=0.39 χ2=0.23; p=0.63  
    
MBL2 AO    
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A 320 (0.79) 95 (0.78) ref 
O 86 (0.21) 27 (0.22) p=0.80; CI=0.57-1.61; OR=0.95 
A/A 128 (0.63) 39 (0.64) ref 
A/O 64 (0.31) 17 (0.28) p=0.75; CI=0.58-2.34; OR=1.15 
O/O 11 (0.05) 5 (0.08) p=0.54; CI=0.1920-2.62; OR=0.67 
HWE χ2=0.63; p=0.43 χ2=2.23; p=0.13  
    
MBL production    
HP 117 (0.58) 36 (0.59) ref 
LP 50 (0.25) 16 (0.26) p=1.00; CI=0.50-2.03; OR=0.96 
DP 36 (0.18) 9 (0.15) p=0.69; CI=0.52-3.18; OR=1.23 
    
Haplotypes    
HYA 113 (0.28) 37 (0.30) ref 
LXA 104 (0.26) 30 (0.25) p=0.68; CI=0.63-2.05; OR=1.13 
LYA 106 (0.26) 28 (0.23) p=0.48; CI=0.68-2.26; OR=1.24 
LYO 62 (0.15) 20 (0.16) p=1.00; CI=0.52-2.01; OR=1.01 
HYO 21 (0.05) 7 (0.06) p=1.00; CI=0.36-2.96; OR=0.98 
 
Abbreviations: HCV = Hepatitis C virus; HC = healthy controls; MBL = mannose binding protein C; HWE = Hardy 
Weinberg equilibrium; HP = high producer (HYA/HYA, HYA/LYA, LYA/LYA, HYA/LXA, LYA/LXA); LP = low 
producer (LXA/LXA, HYA/O, LYA/ O); DP = deficient producer (LXA/O, O/O) 
 
 
Table 2: MBL2 polymorphism allele, genotype and haplotype counts (and frequencies) in HCV 
infected patients treated with IFN therapy classified as sustained virological responder (SVR) and 
non responder (NR). 
 
HCV infection NR SVR NR vs. SVR 
 n=62 n=79  
    
MBL2 H/L    
L 81 (0.65) 101 (0.64) ref 
H 43 (0.34) 57 (0.36) p=0.90; CI=0.56-1.58; OR=0.94 
L/L 25 (0.40) 31 (0.39) ref 
H/L 31 (0.50) 39 (0.50) p=1.00; CI=0.47-2.18; OR=1.01 
H/H 6 (0.10) 9 (0.11) p=1.00; CI=0.22-2.98; OR=0.84 
HWE χ2=0.67;p=0.41 χ2=0.39; p=0.53  
    
MBL2 X/Y    
Y 94 (0.76) 115 (0.73) ref 
X 30 (0.24) 43 (0.27) p=0.59; CI=0.48-1.51; OR=0.85 
Y/Y 36 (0.58) 41 (0.52) ref 
X/Y 22 (0.35) 33 (0.42) p=0.48; CI=0.35-1.62; OR=0.76 
X/X 4 (0.06) 5 (0.06) p=1.00; CI=0.17-4.60; OR=0.91 
HWE χ2=0.06; p=0.80 χ2=0.23; p=0.63  
    
    
MBL2 AO    
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A 103 (0.83) 116 (0.73) ref 
O 21 (0.17) 42 (0.27) p=0.06; CI=0.30-1.05; OR=0.56 
A/A 43 (0.69) 44 (0.56) ref 
A/O 17 (0.27) 28 (0.35) p=0.27; CI=0.28-1.37; OR=0.62 
O/O 2 (0.03) 7 (0.09) p=0.17; CI=0.03-1.67; OR=0.29 
HWE χ2=0.04; p=0.84 χ2=0.67; p=0.41  
    
MBP production    
HP 39 (0.63) 39 (0.49) ref 
LP 17 (0.27) 21 (0.27) p=0.69; CI=0.34-1.89; OR=0.81 
DP 6 (0.10) 19 (0.24) p=0.04; CI=0.09-0.94; OR=0.32 
    
Haplotypes    
HYA 41 (0.33) 42 (0.27) ref 
LXA 32 (0.26) 43 (0.27) p=0.43; CI=0.39-1.50; OR=0.76 
LYA 33 (0.27) 33 (0.21) p=1.00; CI=0.51-2.06; OR=1.02 
LYO 16 (0.13) 25 (0.16) p=0.34; CI=0.28-1.49; OR=0.66 
HYO 2 (0.02) 15 (0.09) p=0.01; CI=0.01-0.65; OR=0.14 
 
Abbreviations: HCV = Hepatitis C virus; NR = non responder; SVR= sustained virological responder; MBL = mannose 
binding protein C; HWE = Hardy Weinberg equilibrium; HP = high producer (HYA/HYA, HYA/LYA, LYA/LYA, 
HYA/LXA, LYA/LXA); LP = low producer (LXA/LXA, HYA/O, LYA/ O); DP = deficient producer (LXA/O, O/O) 
 
 
Table 3: MBL2 polymorphism allele, genotype and haplotype counts (and frequencies) in genotype 
1 HCV infected patients treated with IFN therapy classified as sustained virological responder 
(SVR) and non responder. (NR). 
 
HCV genotype 1 
infection 
NR SVR NR vs. SVR 
 n=46 n=33  
    
MBL2 H/L    
L 59 (0.64) 38 (0.58) ref 
H 33 (0.36) 28 (0.42) p=0.41; CI=0.38-1.53; OR=0.76 
L/L 18 (0.39) 11 (0.33) ref 
H/L 23 (0.50) 16 (0.48) p=1.00; CI=0.29-2.62; OR=0.88 
H/H 5 (0.11) 6 (0.18) p=0.48; CI=0.10-2.59; OR=0.52 
HWE χ2=0.35; p=0.57 χ2=0.002; p=0.96  
    
MBL2 X/Y    
Y 69 (0.75) 52 (0.79) ref 
X 23 (0.25) 14 (0.21) p=0.70; CI=0.55-2.87; OR=1.24 
Y/Y 26 (0.56) 21 (0.64) ref 
X/Y 17 (0.36) 10 (0.30) p=0.63; CI=0.47-4.10; OR=1.37 
X/X 3 (0.07) 2 (0.06) p=1.00; CI=0.12-15.70; OR=1.21 
HWE χ2=0.01; p=0.92 χ2=0.29; p=0.59  
    
    
MBL2 AO    
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A 79 (0.86) 45 (0.68) ref 
O 13 (0.14) 21 (0.32) p=0.01; CI=0.15-0.82; OR=0.35 
A/A 34 (0.74) 17 (0.51) ref 
A/O 11 (0.24) 11 (0.33) p=0.20; CI=0.16-1.57; OR=0.50 
O/O 1 (0.02) 5 (0.15) p=0.03; CI=0.002-1.03; OR=0.10 
HWE χ2=0.01; p=0.92 χ2=1.77; p=0.18  
    
MBP production    
HP 31 (0.67) 15 (0.45) ref 
LP 12 (0.26) 12 (0.36) p=0.20; CI=0.16-1.50; OR=0.49 
DP 3 (0.07) 6 (0.18) p=0.07; CI=0.03-1.35; OR=0.25 
    
Haplotypes    
HYA 32 (0.35) 21 (0.32) ref 
LXA 23 (0.25) 14 (0.21) p=1.00; CI=0.42-2.81; OR=1.08 
LYA 25 (0.26) 12 (0.18) p=0.51; CI=0.52-3.66; OR=1.36 
LYO 11 (0.12) 12 (0.18) p=0.33; CI=0.20-1.81; OR=0.61 
HYO 1 (0.01) 7 (0.10) p=0.02; CI=0.00-0.84; OR=0.10 
 
 
Abbreviations: HCV = Hepatitis C virus; NR = non responder; SVR= sustained virological responder; MBL = mannose 
binding protein C; HWE = Hardy Weinberg equilibrium; HP = high producer (HYA/HYA, HYA/LYA, LYA/LYA, 
HYA/LXA, LYA/LXA); LP = low producer (LXA/LXA, HYA/O, LYA/ O); DP = deficient producer (LXA/O, O/O) 
 
 
Table 4: MBL2 polymorphism allele, genotype and haplotype counts (and frequencies) in genotypes 
other than 1 HCV infected patients treated with IFN therapy classified as sustained virological 
responder (SVR) and non responder (NR). 
 
HCV genotype other 
than 1 infection 
NR SVR NR vs. SVR 
 n=16 n=46  
    
MBL2 H/L    
L 22 (0.69) 63 (0.68) ref 
H 10 (0.31) 29 (0.32) p=1.00; CI=0.37-2.52; OR=0.99 
L/L 7 (0.44) 20 (0.43) ref 
H/L 8 (0.50) 23 (0.50) p=1.00; CI=0.26-3.86; OR=0.99 
H/H 1 (0.06) 3 (0.07) p=1.00; CI=0.01-14.38; OR=0.95 
HWE χ2=0.43; p=0.51 χ2=1.15; p=0.28  
    
MBL2 X/Y    
Y 23 (0.72) 63 (0.68) ref 
X 9 (0.28) 29 (0.32) p=0.82; CI=0.31-2.21; OR=0.85 
Y/Y 8 (0.50) 20 (0.43) Ref 
X/Y 7 (0.44) 23 (0.50) p=0.77; CI=0.20-2.90; OR=0.76 
X/X 1 (0.06) 3 (0.07) p=1.00; CI=0.01-12.39; OR=0.84 
HWE χ2=0.11; p=0.74 χ2=1.15; p=0.28  
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MBL2 AO    
A 26 (0.81) 71 (0.77) ref 
O 6 (0.19) 21 (0.23) p=0.80; CI=0.23-2.30; OR=0.78 
A/A 11 (0.69) 27 (0.59) ref 
A/O 4 (0.25) 17 (0.37) p=0.54; CI=0.12-2.39; OR=0.58 
O/O 1 (0.06) 2 (0.04) p=1.00; CI=0.02-25.79; OR=1.22 
HWE χ2=0.51; p=0.47 χ2=0.11; p=0.74  
    
MBP production    
HP 10 (0.63) 24 (0.52) ref 
LP 4 (0.25) 9 (0.20) p=1.00; CI=0.19-5.05; OR=1.06 
DP 2 (0.12) 13 (0.28) p=0.30; CI=0.03-2.18; OR=0.38 
    
Haplotypes    
HYA 9 (0.28) 21 (0.23) ref 
LXA 9 (0.28) 29 (0.31) p=0.59; CI=0.21-2.47; OR=0.73 
LYA 8 (0.25) 21 (0.23) p=1.00; CI=0.24-3.18; OR=0.89 
LYO 5 (0.16) 13 (0.13) p=1.00; CI=0.19-3.83; OR=0.90 
HYO 1 (0.03) 8 (0.09) p=0.40; CI=0.01-2.85; OR=0.30 
 
 
Abbreviations: HCV = Hepatitis C virus; NR = non responder; SVR= sustained virological responder; MBL = mannose 
binding protein C; HWE = Hardy Weinberg equilibrium; HP = high producer (HYA/HYA, HYA/LYA, LYA/LYA, 
HYA/LXA, LYA/LXA); LP = low producer (LXA/LXA, HYA/O, LYA/ O); DP = deficient producer (LXA/O, O/O) 
 
 
Table 5: characteristics of the studies included in the meta-analysis 
 
Study Ethnicity 
Patients 
man/woman 
age n. controls n. patients 
Halla et al. Brazilian 97/89 53 232 186 
Pedroso et al. Euro-Brazilian 65/37 51 102 102 
Matsushita et al. Japanese NA NA 218 159 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
